These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 38997808)
1. Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma. Shao G; Cui X; Wang Y; Luo S; Li C; Jiang Y; Cai D; Li N; Li X CNS Neurosci Ther; 2024 Jul; 30(7):e14791. PubMed ID: 38997808 [TBL] [Abstract][Full Text] [Related]
2. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218 [TBL] [Abstract][Full Text] [Related]
3. Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Li J; Yang J; Jiang S; Tian Y; Zhang Y; Xu L; Hu B; Shi H; Li Z; Ran G; Huang Y; Ruan S Biomaterials; 2024 Dec; 311():122708. PubMed ID: 39047538 [TBL] [Abstract][Full Text] [Related]
4. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade. Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167 [TBL] [Abstract][Full Text] [Related]
5. The N Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G Front Immunol; 2021; 12():653711. PubMed ID: 34354698 [TBL] [Abstract][Full Text] [Related]
6. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages. Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338 [TBL] [Abstract][Full Text] [Related]
7. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429 [TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515 [TBL] [Abstract][Full Text] [Related]
9. Local Targeting of NAD Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997 [TBL] [Abstract][Full Text] [Related]
10. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma. Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817 [TBL] [Abstract][Full Text] [Related]
11. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G Front Immunol; 2021; 12():637146. PubMed ID: 34025646 [TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579 [No Abstract] [Full Text] [Related]
13. Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy. Kang Y; Yan J; Han X; Wang X; Wang Y; Song P; Su X; Rauf A; Jin X; Pu F; Zhang H ACS Appl Mater Interfaces; 2024 Jul; 16(28):36131-36141. PubMed ID: 38979627 [TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy strategies for glioblastoma. Chan HY; Choi J; Jackson C; Lim M J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705 [TBL] [Abstract][Full Text] [Related]
15. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma. Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A Front Immunol; 2021; 12():650105. PubMed ID: 34394072 [TBL] [Abstract][Full Text] [Related]
16. Blocking LTB Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900 [TBL] [Abstract][Full Text] [Related]
17. The CEBPB Yang Y; Jin X; Xie Y; Ning C; Ai Y; Wei H; Xu X; Ge X; Yi T; Huang Q; Yang X; Jiang T; Wang X; Piao Y; Jin X Theranostics; 2024; 14(10):4107-4126. PubMed ID: 38994023 [No Abstract] [Full Text] [Related]
18. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966 [TBL] [Abstract][Full Text] [Related]
20. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Yang F; He Z; Duan H; Zhang D; Li J; Yang H; Dorsey JF; Zou W; Nabavizadeh SA; Bagley SJ; Abdullah K; Brem S; Zhang L; Xu X; Byrne KT; Vonderheide RH; Gong Y; Fan Y Nat Commun; 2021 Jun; 12(1):3424. PubMed ID: 34103524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]